Fig. 2: Tumor response. | Nature Communications

Fig. 2: Tumor response.

From: The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial

Fig. 2: Tumor response.

A The spider plot showing patient responses by week based on RECIST v1.1. B The spider plot showing patient responses by week based on mRECIST. C The waterfall plot showing the percentage change in target lesions from baseline based on RECIST v1.1. D The waterfall plot showing the percentage change in target lesions from baseline based on mRECIST. E The swimming plot showing tumor responses during treatment based on RECIST v1.1. F The swimming plot showing tumor responses during treatment based on mRECIST. QD once every day, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable.

Back to article page